Literature DB >> 31435712

Human skin-derived ABCB5+ stem cell injection improves liver disease parameters in Mdr2KO mice.

Vanessa Hartwig1, Bedair Dewidar1,2, Tao Lin1, Anne Dropmann1, Christoph Ganss3,4, Mark Andreas Kluth3,4, Nils Tappenbeck3, Lysann Tietze5, Bruno Christ5, Markus Frank6, Roger Vogelmann1, Matthias Philip Alexander Ebert1, Steven Dooley7.   

Abstract

Although liver transplantation is a potential effective cure for patients with end-stage liver diseases, this strategy has several drawbacks including high cost, long waiting list, and limited availability of liver organs. Therefore, stem cell-based therapy is presented as an alternative option, which showed promising results in animal models of acute and chronic liver injuries. ABCB5+ cells isolated from skin dermis represent an easy accessible and expandable source of homogenous stem cell populations. In addition, ABCB5+ cells showed already promising results in the treatment of corneal and skin injury. To date, the effect of these cells on liver injury is still unknown. In the current study, sixteen weeks old Mdr2KO mice were i.v. injected with 500,000 ABCB5+ cells using different experimental setups. The effects of cellular therapy on inflammation, fibrosis, apoptosis, and proliferation were analyzed in the collected liver tissues. Toxicity of ABCB5+ cells was additionally investigated in mice with partial liver resection. In vitro, the fibrosis- and inflammatory-modulating effects of supernatant from ABCB5+ cells were examined in the human hepatic stellate cell line (LX-2). Cell injections into fibrotic Mdr2KO mice as well as into mice upon partial liver resection have no signs of toxicity with regard to cell transformation, cellular damage, fibrosis or inflammation as compared to controls. We next investigated the effects of ABCB5+ cells on established biliary liver fibrosis in the Mdr2KO mice. ABCB5+ cells to some extent influenced the shape of the liver inflammatory response and significantly reduced the amount of collagen deposition, as estimated from quantification of sirius red staining. Furthermore, reduced apoptosis and enhanced death compensatory proliferation resulted from ABCB5+ cell transformation. The stem cells secreted several trophic factors that activated TGF-β family signaling in cultured LX-2 hepatic stellate cells (HSCs), therewith shaping cell fate to an αSMAhigh, Vimentinlow phenotype. Taken together, ABCB5+ cells can represent a safe and feasible strategy to support liver regeneration and to reduce liver fibrosis in chronic liver diseases.

Entities:  

Keywords:  ABCB5; Cell therapy; Liver fibrosis; Mdr2KO; Mesenchymal stromal cells

Mesh:

Substances:

Year:  2019        PMID: 31435712     DOI: 10.1007/s00204-019-02533-3

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  2 in total

1.  Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: off-the-shelf GMP-manufactured donor-independent ATMP.

Authors:  Seda Ballikaya; Samar Sadeghi; Elke Niebergall-Roth; Laura Nimtz; Jens Frindert; Alexandra Norrick; Nicole Stemler; Nicole Bauer; Yvonne Rosche; Vanessa Kratzenberg; Julia Pieper; Tina Ficek; Markus H Frank; Christoph Ganss; Jasmina Esterlechner; Mark A Kluth
Journal:  Stem Cell Res Ther       Date:  2020-11-16       Impact factor: 6.832

2.  Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data.

Authors:  Andreas Kerstan; Elke Niebergall-Roth; Jasmina Esterlechner; Hannes M Schröder; Martin Gasser; Ana M Waaga-Gasser; Matthias Goebeler; Katrin Rak; Philipp Schrüfer; Sabrina Endres; Petra Hagenbusch; Korinna Kraft; Kathrin Dieter; Seda Ballikaya; Nicole Stemler; Samar Sadeghi; Nils Tappenbeck; George F Murphy; Dennis P Orgill; Natasha Y Frank; Christoph Ganss; Karin Scharffetter-Kochanek; Markus H Frank; Mark A Kluth
Journal:  Cytotherapy       Date:  2020-10-01       Impact factor: 5.414

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.